Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

GSK2816126

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

GSK

Drug class:

EZH2 inhibitor

Related drugs:

MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	panobinostat + GSK2816126 Sensitive: D – Preclinical panobinostat + GSK2816126 Sensitive : D	panobinostat + GSK2816126 Sensitive: D – Preclinical panobinostat + GSK2816126 Sensitive : D
EZH2 Y646	Melanoma	EZH2 Y646	Melanoma	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D
ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D
EZH2 Y641F	Melanoma	EZH2 Y641F	Melanoma	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D
ARID1A mutation	Bladder Cancer	ARID1A mutation	Bladder Cancer	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D	GSK2816126 Sensitive: D – Preclinical GSK2816126 Sensitive : D